NEUBASE THERAPEUTICS
NBSE
 Delayed - 01/15 04:00:00 pm |
|
| 7.19USD | -3.49% |
Upcoming events on NEUBASE THERAPEUTICS, INC.
| 04/01/21 | Q1 2021 Earnings Release (Projected) |
| 05/20/21 | Interim 2021 Earnings Release (Projected) |
| 03/31/22 | Q1 2022 Earnings Release (Projected) |
Past events on NEUBASE THERAPEUTICS, INC.
| 01/14/21 | FY 2021 Earnings Release (Projected) |
| 01/11/21 | 06:00am | H.C. Wainwright Bioconnect Conference |
| 01/06/21 | LifeSci Advisors Corporate Access Event |
| 12/23/20 | 04:05pm | FY 2020 Earnings Release |
Upcoming sector events for NEUBASE THERAPEUTICS, INC.
| 01/19/21 | 04:30pm | UNITED THERAPEUTICS CORPORATION : Tyvaso Study Results Call |
| 01/19/21 | AKESO, INC. : R&D Day |
| 01/20/21 | 06:00am | EVOTEC SE : Unicredit & KeplerCheuvreux German Corporate Conference |
| 01/21/21 | 12:00am | SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. : Extraordinary Shareholders Meeting |
Past sector events for NEUBASE THERAPEUTICS, INC.
| 01/15/21 | GUARDANT HEALTH, INC. : American society of clinical oncology gastrointestinal cancers symposium - abstract no : #61 |
| 01/15/21 | GUARDANT HEALTH, INC. : American society of clinical oncology gastrointestinal cancers symposium - abstract no : #119 |
| 01/15/21 | GUARDANT HEALTH, INC. : American society of clinical oncology gastrointestinal cancers symposium - abstract no : #39 |
| 01/15/21 | GUARDANT HEALTH, INC. : American society of clinical oncology gastrointestinal cancers symposium - abstract no : tps #142 |
Annual results
 Previous year | Next Year |
| Annual results | 2020 | 2021 (e) | |
| Sales M $ |
Released Forecast Spread | -17,1 -16,8 -1,8% | -24,5 |
| Operating income (EBITDA) M $ |
Released Forecast Spread | -17,4 -17,3 -0,30% | -24,4 |
| Operating profit (EBIT) M $ |
Released Forecast Spread | -17,4 -17,3 -0,30% | -24,4 |
| Pre-Tax Profit (EBT) $ |
Released Forecast Spread | -0,89 -0,89 0,00% | -1,00 |
| Announcement Date | 12/23/2020 | ||
Quarterly / Semiannualy publications
| Previous period | Next period |
| Quarterly results | 2020 Q4 | 2021 Q1 (e) | |
| Sales M $ |
Released Forecast Spread | -5,11 -4,74 -7,8% | -5,31 |
| Operating income (EBITDA) M $ |
Released Forecast Spread | -4,70 -4,71 0,18% | -5,21 |
| Operating profit (EBIT) M $ |
Released Forecast Spread | -4,70 -4,71 0,18% | -5,21 |
| Pre-Tax Profit (EBT) $ |
Released Forecast Spread | -0,20 -0,20 -0,84% | -0,24 |
| Announcement Date | 12/23/2020 | ||
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
